TT-00920

Primary objective: To study the safety and tolerability of single and multiple ascending doses of TT-00920 tablets in healthy subjects. Secondary objective: To determine the plasma pharmacokinetics (PK) characteristics of TT-00920 and its main metabolites after single and multiple oral administration in healthy subjects. Exploratory objectives: ① To explore the changes in biomarkers in blood and urine after single and multiple oral administration of TT-00920 tablets in healthy subjects; ② To explore the urine PK characteristics of TT-00920 and its main metabolites after single and multiple oral administration in healthy subjects; ③ To explore the genetic polymorphism of drug metabolizing enzymes